Patient demographics
| Median age (minimum-maximum), y | |
| At time of thrombosis | 14.0 (0.1-18.0) |
| At time of blood sample | 15.0 (1.0-19.0) |
| Median weight (minimum-maximum), kg | 61.0 (2.3-101.0) |
| Sex, n (%) | |
| Female | 32 (54) |
| Ethnic origin, n (%) | |
| White | 59 (100) |
| Underlying medical condition, n (%) | |
| Cardiac | 14 (22.0) |
| Oral contraceptives | 9 (15.3) |
| Infection | 6 (8.5) |
| None | 5 (8.5) |
| Obesity | 5 (6.8) |
| Other | 20 (32.2) |
| Type of thrombosis, n (%) | |
| Deep vein thrombosis (upper limb, popliteal veins) | 20 (33.3) |
| Pulmonary embolism | 19 (31.6) |
| Renal vein thrombosis | 1 (1.7) |
| Femoral or iliac thrombosis | 18 (30) |
| Hepatic/intracardiac | 3 (5.1) |
| Thromboembolic ischemic stroke/sinovenous thrombosis | 9 (15.0) |
| Recurrence | |
| n (%) | 15 (25.4) |
| Time to recurrence, median (minimum-maximum), months | 126.8 (3.6-58.8) |
| Postthrombotic syndrome at 2-year follow-up, n (%) | 15 (25.4) |
| VKA type, n (%) | |
| Warfarin | 34 (55.9) |
| Phenprocoumon | 26 (44.1) |
| Median time to therapeutic range (minimum-maximum), d | 7 (2-14) |
| Median INR at day 7 (minimum-maximum) | 2.3 (1.4-3.2) |
| VKORC1, n (%) | |
| AA | 7 (11.9) |
| GA | 25 (42.4) |
| GG | 27 (45.7) |
| CYP2C9, n (%) | |
| 1.1 | 39 (66.1) |
| 1.2 | 11 (18.6) |
| 1.3 | 8 (13.6) |
| 2.2 | 1 (1.7) |
| 2.3/3.3 | 0 (0) |
| Median age (minimum-maximum), y | |
| At time of thrombosis | 14.0 (0.1-18.0) |
| At time of blood sample | 15.0 (1.0-19.0) |
| Median weight (minimum-maximum), kg | 61.0 (2.3-101.0) |
| Sex, n (%) | |
| Female | 32 (54) |
| Ethnic origin, n (%) | |
| White | 59 (100) |
| Underlying medical condition, n (%) | |
| Cardiac | 14 (22.0) |
| Oral contraceptives | 9 (15.3) |
| Infection | 6 (8.5) |
| None | 5 (8.5) |
| Obesity | 5 (6.8) |
| Other | 20 (32.2) |
| Type of thrombosis, n (%) | |
| Deep vein thrombosis (upper limb, popliteal veins) | 20 (33.3) |
| Pulmonary embolism | 19 (31.6) |
| Renal vein thrombosis | 1 (1.7) |
| Femoral or iliac thrombosis | 18 (30) |
| Hepatic/intracardiac | 3 (5.1) |
| Thromboembolic ischemic stroke/sinovenous thrombosis | 9 (15.0) |
| Recurrence | |
| n (%) | 15 (25.4) |
| Time to recurrence, median (minimum-maximum), months | 126.8 (3.6-58.8) |
| Postthrombotic syndrome at 2-year follow-up, n (%) | 15 (25.4) |
| VKA type, n (%) | |
| Warfarin | 34 (55.9) |
| Phenprocoumon | 26 (44.1) |
| Median time to therapeutic range (minimum-maximum), d | 7 (2-14) |
| Median INR at day 7 (minimum-maximum) | 2.3 (1.4-3.2) |
| VKORC1, n (%) | |
| AA | 7 (11.9) |
| GA | 25 (42.4) |
| GG | 27 (45.7) |
| CYP2C9, n (%) | |
| 1.1 | 39 (66.1) |
| 1.2 | 11 (18.6) |
| 1.3 | 8 (13.6) |
| 2.2 | 1 (1.7) |
| 2.3/3.3 | 0 (0) |